Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study.
Author(s): Guadalix S, Martinez-Diaz-Guerra G, Lora D, Vargas C, Gomez-Juaristi M, Cobaleda B, Gonzalez EM, Hawkins F
Affiliation(s): Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain.
Publication date & source: 2011-07, Transpl Int., 24(7):657-65. Epub 2011 Apr 5.
Publication type: Randomized Controlled Trial; Research Support, Non-U.S. Gov't
The aim of this study was to investigate the effect of risedronate (RIS) on bone loss and bone turnover markers after liver transplantation (LT). Patients with osteopenia or osteoporosis within the first month after LT were randomized to receive RIS 35 mg/week plus calcium 1000 mg/day and vitamin D(3) 800 IU/day (n = 45) or calcium and vitamin D(3) at same dosages (n = 44). Primary endpoint was change in bone mineral density (BMD) 6 and 12 months after LT. Secondary endpoints included changes in serum beta-CrossLaps (beta-CTX) and procollagen type 1 amino-terminal peptide (P1NP) and fracture rate. Spine X-rays were obtained at baseline and after 12 months. There was no significant difference in BMD changes between both treatment groups at any sites; either at 6 or 12 months. Spine BMD increased in both groups at 12 months vs. baseline (P = 0.001). RIS patients had a significant increase in intertrochanteric BMD at 12 months (P < 0.05 vs. baseline). Serum beta-CTX decreased in both groups (P < 0.01), with significant differences between groups at 3 months. No significant difference in vertebral fracture incidence was found. After 12 months, BMD improved at lumbar spine and did not change at hip in both groups. Significant differences between both groups were not found. Other factors (calcium and vitamin D replacement, early prednisone withdrawal) seem to have also positive effects in BMD. (c) 2011 The Authors. Transplant International (c) 2011 European Society for Organ Transplantation.